Skip to content
Screener

Inhibrx Biosciences, Inc. INBX Business Segments — Equipment, depreciation, and facility

Similar metrics at other companies

ImmunityBio, Inc. logo
IBRXReportable Segment — Equipment, depreciation, and facility costs
$13.59M+3.0%
BlueLinx Holdings logo
BXCReportable Segment — Depreciation of property and equipment
$9.88M+14.9%
PCB Bancorp logo
PCBReportable Segment — Depreciation of premises and equipment
$508K-7.3%
Concentra Group Holdings Parent logo
CONReportable Segment — Facility expenses
$52.22M+7.9%
XPEL, Inc. logo
XPELReportable Segment — Facility expenses
$3.17M+14.1%
Prime Medicine logo
PRMEReportable Segment — Facility related
$10.58M-23.2%

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.3B+320%
Enterprise value$1.32B+474%

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept inbx:ResearchAndDevelopmentExpenseEquipmentDepreciationAndFacility.

The source filing: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026.

Filed
Mar 19, 2026, 4:00 PM EDT
Fiscal year
FY2025
Accession
0002007919-26-000006
Line itemYEAR ENDEDDECEMBER 31, 2025YEAR ENDEDDECEMBER 31, 2024
Personnel35,37272,790
Clinical trials35,33947,665
Contract manufacturing19,59055,643
Equipment, depreciation, and facility10,2279,693
Other research and development12,50017,952
General and administrative expense
Merger-related68,061
Personnel14,48137,649

Item 8. Financial Statements and Supplementary Data.

FAQ

What is Inhibrx Biosciences, Inc.'s business segments — equipment, depreciation, and facility?
Inhibrx Biosciences, Inc. (INBX) reported business segments — equipment, depreciation, and facility of $2.56M in Q4 2025.
How has Inhibrx Biosciences, Inc.'s business segments — equipment, depreciation, and facility changed year-over-year?
Inhibrx Biosciences, Inc.'s business segments — equipment, depreciation, and facility increased by 5.5% year-over-year, from $2.42M to $2.56M.
What is the long-term trend for Inhibrx Biosciences, Inc.'s business segments — equipment, depreciation, and facility?
Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s business segments — equipment, depreciation, and facility has grown at a 17.6% compound annual growth rate (CAGR), from $7.4M to $10.23M.
What does business segments — equipment, depreciation, and facility mean?
Includes the depreciation of laboratory equipment and the costs associated with maintaining facilities used by the reportable segment. It represents the fixed overhead required to sustain the physical infrastructure necessary for research and development.

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — equipment, depreciation, and facility.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude